Conference Coverage

Skin patch therapy for peanut allergy wins plaudits


 

AT 2015 AAAAI ANNUAL MEETING

References

“I think this concept of using a low amount of protein in a convenient, safe way could change the way we do immunotherapy,” Dr. Sampson predicted.

Asked to comment, peanut allergy researcher Dr. Brian P. Vickery of the University of North Carolina, Chapel Hill, agreed with Dr. Sampson’s assessment that patch therapy could be a game changer, especially given that there is no FDA-approved treatment for peanut allergy.

“Right now the standard of care is avoidance. So anything that improves upon that to allow a margin of safety that lets a patient get along in the world with the reassurance that a contamination event up to, say, a gram would be well tolerated would be transformative,” he said.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

FDA approves Ragwitek, third sublingual allergy med in a month
MDedge Pediatrics
‘Shotgun’ skin prick testing for food allergy held flawed
MDedge Pediatrics
Link between early exposure to acetaminophen and childhood asthma found weak, overstated
MDedge Pediatrics
Don’t be scared of red eye, expert says
MDedge Pediatrics
FDA approves pediatric dosage of QNASL
MDedge Pediatrics
Guideline clarifies first-line treatment for allergic rhinitis
MDedge Pediatrics
Get the baby a dog: Infants’ gut biota seen to affect allergy risk
MDedge Pediatrics